RPG Life Sciences Ltd
RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in the domestic and international market.[1]
The company is a part of RPG group which is a diversified conglomerate with interests in areas of infrastructure, tyres, information technology, pharmaceuticals, energy and plantations.[2] The group is headed by Harsh Goenka.[3]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Dividend Payout % |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Equity Capital |
Reserves |
Preference Capital |
Total Liabilities |
CWIP |
Investments |
Total Assets |
Cash Flows
Figures in Rs. Crores
Net Cash Flow |
Ratios
Figures in Rs. Crores
Debtor Days |
Inventory Days |
Days Payable |
Cash Conversion Cycle |
Working Capital Days |
ROCE % |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
- Closure of Trading Window 2d
-
Agreement For Subscription To Shares
11 Mar - Execution of Share Subscription and Shareholders'' Agreement with Sunpound Solar Private Limited (Sunpound) Special Purpose Vehicle (SPV) for subscribing to at least 26% of the …
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 8 Mar
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 8 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Oct 2023Transcript PPT
-
Jul 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Oct 2022Transcript PPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2019TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Jun 2016TranscriptNotesPPT
Domestic Formulations Segment (~65% of revenues)
The company develops, manufactures, and markets branded formulations in India & Nepal. Its product portfolio includes various products which are sold under its key brands i.e. Azaron, Mofetyl, Lomitil, Arpimune, Imunotac, Serenace, etc. It has a presence in various therapeutic segments such as nephrology, rheumatology, Oncology, Orthopaedics, Gastroenterology, and others. [1]